Histone deacetylases

Current Opinion in Pharmacology

Volumn 3, Issue 4, 2003, Pages 344-351

  Marks, Paul A ^a   Miller, Thomas ^b   Richon, Victoria M ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Aton Pharma Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; ALIPHATIC CARBOXYLIC ACID; ALPHA KETOAMIDE; APICIDIN; ARYLBUTYRIC ACID DERIVATIVE; BENZAMIDE; BENZAMIDE DERIVATIVE; CINNAMIC ACID DERIVATIVE; CYCLOPEPTIDE; CYTOTOXIC AGENT; DEPSIPEPTIDE; FR 901228; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; KETONE DERIVATIVE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OXAMFLATIN; PIVALOYLOXYMETHYL BUTYRATE; PROTEIN P21; SULFONAMIDE HYDROXAMIC ACID; TETRAPEPTIDE; TRICHOSTATIN A; TRIFLUOROMETHYL KETONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VASCULOTROPIN; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CELL DIFFERENTIATION; CELL GROWTH; CHROMATIN; DRUG BIOAVAILABILITY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG DESIGN; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0041302197     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(03)00084-5     Document Type: Review

References (52)

1. Spotswood H.T. Turner B.M. An increasingly complex code J Clin Invest 110 2002 577-582
2. Grozinger C.M. Schreiber S.L. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors Chem Biol 9 2002 3-16
3. Jenuwein T. Allis C.D. Translating the histone code Science 293 2001 1074-1080
4. Zhang Y. Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails Genes Dev 15 2001 2343-2360
5. Agalioti T. Chen G. Thanos D. Deciphering the transcriptional histone acetylation code for a human gene Cell 111 2002 381-392
6. Richards E.J. Elgin S.C. Epigenetic codes for heterochromatin formation and silencing: rounding up the usual suspects Cell 108 2002 489-500
7. Timmermann S. Lehrmann H. Polesskaya A. Harel-Bellan A. Histone acetylation and disease Cell Mol Life Sci 58 2001 728-736
8. Wang C. Fu M. Mani S. Wadler S. Senderowicz A.M. Pestell R.G. Histone acetylation and the cell-cycle in cancer Front Biosci 6 2001 D610-D629
9. Jones P. Baylin S.B. The fundamental role of epigenetic events in cancer Nat Rev Genet 3 2002 415-428
10. Marks P. Rifkind R.A. Richon V.M. Breslow R. Miller T. Kelly W.K. Histone deacetylases and cancer: causes and therapies Nat Rev Cancer 1 2001 194-202
11. Kelly W.K. O'Connor O.A. Marks P.A. Histone deacetylase inhibitors: from target to clinical trials Expert Opin Investig Drugs 11 2002 1695-1713
12. Butler L.M. Zhou X. Xu W.-S. Scher H.I. Rifkind R.A. Marks P.A. Richon V.M. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin Proc Natl Acad Sci USA 99 2002 11700-11705
13. Suzuki H. Gabrielson E. Chen W. Anbazhagan R. van Engeland M. Weijenberg M.P. Herman J.G. Baylin S.B. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer Nat Genet 31 2002 141-149
14. Rogione F. Crinite V. Della-Pietra V. Genes modulated by histone acetylation as new effectors of butyrate activity FEBS Lett 499 2001 199-204
15. Glaser K.B. Staver M.J. Waring J.F. Stender J. Ulrich R.G. Davidsen S.K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines Mol Cancer Ther 2 2003 151-163
16. Grozinger C.M. Chao E.D. Blackwell H.E. Moazed D. Schreiber S.L. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening J Biol Chem 276 2001 38837-38843
17. De Ruijter A.J. Van Gennip A.H. Caron H.N. Kemp S. Van Kuilenburg A.B. Histone deacetylases: characterisation of the classical HDAC family Biochem J 370 2003 737-749
18. Turner B.M. Cellular memory and the histone code Cell 111 2002 285-291
19. Khochbin S. Verdel A. Lemercier C. Seigneurin-Berny D. Functional significance of histone deacetylase diversity Curr Opin Genet Dev 11 2001 162-166
20. McKinsey T.A. Zhang C.L. Olson E.N. Control of muscle development by dueling HATs and HDACs Curr Opin Genet Dev 11 2001 497-504
21. Finnin M.S. Donigian J.R. Cohen A. Richon V.M. Rifkind R.A. Marks P.A. Breslow R. Pavletich N.P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors Nature 401 1999 188-193
22. Yoshida M. Kijima M. Akita M. Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A J Biol Chem 265 1990 17174-17179
23. Richon V.M. Emiliani S. Verdin E. Webb Y. Breslow R. Rifkind R.A. Marks P.A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases Proc Natl Acad Sci USA 95 1998 3003-3007
24. Curtin M.L. Current patent status of histone deacetylase inhibitors Expert Opinion on Therapeutics Patents 12 2002 1375-1384
25. Bouchain G. Leit S. Frechette S. Khalil E.A. Lavoie R. Moradei O. Woo S.H. Fournel M. Yan P.T. Kalita A. et al. Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors J Med Chem 46 2003 820-830
26. Lavoie R. Bouchain G. Frechette S. Woo S.H. Abou-Khalil E. Leit S. Fournel M. Yan P.T. Trachy-Bourget M.C. Beaulieu C. et al. Design and synthesis of a novel class of histone deacetylase inhibitors Bioorg Med Chem Lett 11 2001 2847-2850
27. Kim Y.B. Lee K.H. Sugita K. Yoshida M. Horinouchi S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase Oncogene 18 1999 2461-2470
28. Su G.H. Sohn T.A. Ryu B. Kern S.E. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library Cancer Res 60 2000 3137-3142
29. Furumai R. Matsuyama A. Kobashi N. Lee K.H. Nishiyama M. Nakajima H. Tanaka A. Komatsu Y. Nishino N. Yoshida M. et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases Cancer Res 62 2002 4916-4921
30. Singh S.B. Zink D.L. Liesch J.M. Mosley R.T. Dombrowski A.W. Bills G.F. Darkin-Rattray S.J. Schmatz D.M. Goetz M.A. Structure and chemistry of apicidins, a class of novel cyclic tetrapeptides without a terminal alpha-keto epoxide as inhibitors of histone deacetylase with potent antiprotozoal activities J Org Chem 67 2002 815-825
31. Furumai R. Komatsu Y. Nishino N. Khochbin S. Yoshida M. Horinouchi S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin Proc Natl Acad Sci USA 98 2001 87-92
32. Phiel C.J. Zhang F. Huang E.Y. Guenther M.G. Lazar M.A. Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen J Biol Chem 276 2001 36734-36741
33. Boivin A.J. Momparler L.F. Hurtubise A. Momparler R.L. Antineoplastic action of 5-aza-2′-deoxycytidine and phenylbutyrate on human lung carcinoma cells Anticancer Drugs 13 2002 869-874
34. Prakash S. Foster B.J. Meyer M. Wozniak A. Heilbrun L.K. Flaherty L. Zalupski M. Radulovic L. Valdivieso M. LoRusso P.M. Chronic oral administration of CI-994: a phase 1 study Invest New Drugs 19 2001 1-11
35. Saito A. Yamashita T. Mariko Y. Nosaka Y. Tsuchiya K. Ando T. Suzuki T. Tsuruo T. Nakanishi O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors Proc Natl Acad Sci USA 96 1999 4592-4597
36. Frey R.R. Wada C.K. Garland R.B. Curtin M.L. Michaelides M.R. Li J. Pease L.J. Glaser K.B. Marcotte P.A. Bouska J.J. et al. Trifluoromethyl ketones as inhibitors of histone deacetylase Bioorg Med Chem Lett 12 2002 3443-3447
37. Van Lint C. Emiliani S. Verdin E. The expression of a small fraction of cellular gene is changed in response to histone hyperacetylation Gene Expr 5 1996 245-254
38. Sambucetti L.C. Fischer D.D. Zabludoff S. Kwon P.O. Chamberlin H. Trogani N. Xu H. Cohen D. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects J Biol Chem 274 1999 34940-34947
39. Richon V.M. Sandhoff T.W. Rifkind R.A. Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation Proc Natl Acad Sci USA 97 2000 10014-10019
40. Lagger G. O'Carroll D. Rembold M. Khier H. Tischler J. Weitzer G. Schuettengruber B. Hauser C. Brunmeir R. Jenuwein T. et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression EMBO J 21 2002 2672-2681
41. Vrana J.A. Decker R.H. Johnson C.R. Wang Z. Jarvis W.D. Richon V.M. Ehinger M. Fisher P.B. Grant S. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53 Oncogene 18 1999 7016-7025
42. Polevoda B, Sherman F: The diversity of acetylated proteins. Genome Biol 2002, 3 reviews0006.
43. Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J 19 2000 1176-1179
44. Freiman R.N. Tjian R. Regulating the regulators: lysine modifications make their mark Cell 112 2003 11-17
45. Yu X. Guo Z.S. Marcu M.G. Neckers L. Nguyen D.M. Chen G.A. Schrump D.S. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228 J Natl Cancer Inst 94 2002 504-513
46. Scott G.K. Marden C. Xu F. Kirk L. Benz C.C. Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen Mol Cancer Ther 1 2002 385-392
47. Kelly W, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L: Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid (SAHA) administered intravenously. Clin Cancer Res 2003, in press.
48. Qiu L. Kelso M.J. Hansen C. West M.L. Fairlie D.P. Parsons P.G. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate Br J Cancer 80 1999 1252-1258
49. Piekarz R.L. Robey R. Sandor V. Bakke S. Wilson W.H. Dahmoush L. Kingma D.M. Turner M.L. Altemus R. Bates S.E. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report Blood 98 2001 2865-2868
50. Sandor V. Bakke S. Robey R.W. Kang M.H. Blagosklonny M.V. Bender J. Brooks R. Piekarz R.L. Tucker E. Figg W.D. et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms Clin Cancer Res 8 2002 718-728
51. Olivares J, Williams A, Olson S, Pauer LR, Grove W: Phase I pharmacokinetic study of CI-994 in combination with carboplatin and paclitaxel in patients with advanced solid tumors. Proc Am Soc Clin Onc 2001:87a.
52. Verdin E, Cohen D, Olsen E, Yao P, Gu W, Atadja P, Marks PA: Reversible acetylation and methylation of chromatin and non-histone proteins: biology and relevance to human disease. Novartis Foundations Symposium 2003, 259; in press.